Arius Research, Inc.

Hoffmann-la Roche Inc.

Luis A G daCruz

David S F Young

Susan E Hahn

Helen P Findlay

Alison L Ferry

Daad Sayegh

Sheung Tat Fan

Ronnie Tung Ping Poon

Terence Kin Wah Lee

This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

Cytotoxicity mediation of cells evidencing surface expression of CD63

The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

Cytotoxicity mediation of cells evidencing surface expression of TROP-2

Growing community of inventors

Toronto, Canada

Luis A G daCruz